Effect of antioxidants on androgen-induced AP-1 and NF-κB DNA-binding activity in prostate carcinoma cells

Journal of the National Cancer Institute

Volumn 91, Issue 14, 1999, Pages 1227-1232

  Ripple, Maureen O ^b   Henry, William F ^d   Schwarze, Steven R ^c   Wilding, George ^a   Weindruch, Richard ^e  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ANDROSTANOLONE; ANTIOXIDANT; ASCORBIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METRIBOLONE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1;

ANTIOXIDANT ACTIVITY; ARTICLE; DRUG DNA BINDING; HORMONAL REGULATION; HUMAN; HUMAN CELL; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; TRANSCRIPTION REGULATION;

EID: 0033591849     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.14.1227     Document Type: Article

References (47)

1. Meikle AW. The endocrinology of the prostate and benign prostatic hyperplasia. In: DeGroot LJ, editor. Endocrinology. 2nd ed. Philadelphia (PA): Saunders; 1989. p. 2152-60.
2. Gormley GJ. Chemoprevention strategies for prostate cancer: the role of 5α-reductase inhibitors. J Cell Biochem Suppl 1992;16H:113-7.
3. Thompson IM, Coltman CA, Brawley OW, Ryan A. Chemoprevention of prostate cancer. Semin Urol 1995;13:122-9.
4. Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995;23:43-62.
5. Nutter LM, Wu YY. Ngo EO, Sierra EE, Gutierrez PL, Abul-Hajj YJ. An o-quinone form of estrogen produces free radicals in human breast cancer cells: correlation with DNA damage. Chem Res Toxicol 1994;7:23-8.
6. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997;6:3-10.
7. Bosland MC, Prinsen MK, Kroes R. Adenocarcinomas of the prostate induced by N-nitroso-N-methylurea in rats pretreated with cyproterone acetate and testosterone. Cancer Lett 1983;18:69-78.
8. Pollard M, Luckert PH. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone. J Natl Cancer Inst 1986;77:583-7.
9. Shirai T, Tamano S, Sano M, Imaida K, Hagiwara A, Futakuchi M, et al. Site-specific effects of testosterone propionate on the prostate of rat pretreated with 3,2′-dimethyl-4-aminobiphenyl: dose-dependent induction of invasive carcinomas. Jpn J Cancer Res 1995; 86:645-8.
10. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998 [published errata appear in CA Cancer J Clin 1998;48:192 and 1998;48: 329]. CA Cancer J Clin 1998;48:6-29.
11. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996:273: 59-63.
12. Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997;89:40-8.
13. Cerutti PA. Prooxidant states and tumor promotion. Science 1985;227:375-81.
14. Oberley TD, Oberley LW. Oxygen radicals and cancer. In: Yu BP, editor. Free radicals in aging. Ann Arbor (MI): CRC Press; 1993. p. 247-67.
15. Dargel R. Lipid peroxidation - a common pathogenetic mechanism? Exp Toxicol Pathol 1992;44:169-81.
16. Ziegler DM. Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. Annu Rev Biochem 1985;54: 305-29.
17. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997;275:1649-52.
18. Muller JM, Rupec RA, Baeuerle PA. Study of gene regulation by NFκ B and AP-1 in response to reactive oxygen intermediates. Methods 1997;11:301-12.
19. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90: 440-6.
20. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995;87: 1767-76.
21. Clark LC, Krongrad A, Slate E, Combs GF, Turnbull BW. Decreased incidence of prostate cancer with selenium (Se) supplementation: results of a RCT [abstract]. FEBS Proc 1998;abstract 4781.
22. Angel P, Karin M. The role of Jun, Fos, and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072: 129-57.
23. Baeuerle PA, Henkel T. Function and activation of NFκB in the immune system. Annu Rev Immunol 1994;12:141-79.
24. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NFκB/IκB family: intimate tales of association and dissociation. Genes Dev 1995;9:2723-35.
25. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993;262:1274-7.
26. Rago R, Mitchen J, Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoeschst 33258 after cell lysis by freezing in distilled water. Anal Biochem 1990;191: 31-4.
27. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19:2499.
28. Feig DI, Reid TM, Loeb LA. Reactive oxygen species in tumorigenesis. Cancer Res 1994;54(7 Suppl):1890s-1894s.
29. Malins DC, Polissar NL, Gunselman SJ. Models of DNA structure achieve almost perfect discrimination between normal prostate, benign prostatic hyperplasia (BPH), and adenocarcinoma and have a high potential for predicting BPH and prostate cancer. Proc Natl Acad Sci U S A 1997;94:259-64.
30. Sies H, Brigelius R, Graf P. Hormones, glutathione status and protein S-thiolation. Adv Enzyme Regul 1987;25:175-89.
31. Finkel T. Oxygen radicals and signaling. Curr Opin Cel Biol 1998;10:248-53.
32. Mignotte B, Vayssiere JL. Mitochondria and apoptosis. Eur J Biochem 1998;252:1-15.
33. Gotoh Y, Cooper JA. Reactive oxygen species-and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J Biol Chem 1998;273:17477-82.
34. Abate C, Patel L, Rauscher FJ 3d, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990;249:1157-61.
35. Meyer M, Schreck R, Muller JM, Baeuerle PA. Redox control of gene expression by eukaryotic transcription factors NF-κB, AP-1 and SRF/TCF. In: Pasquier C, Olivier RY, Auclair C, Packer L, editors. Oxidative stress, cell activation and viral infection. Boston (MA): Birkhauser Verlag; 1994. p. 217-35.
36. Primiano T, Sutter TR, Kensler TW. Redox regulation of genes that protect against carcinogens. Comp Biochem Physiol B Biochem Mol Biol 1997;118:487-97.
37. Toledano MB, Leonard WJ. Modulation of transcription factor NFκB binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A 1991;88:4328-32.
38. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996;10:709-20.
39. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-6.
40. Jonat C, Rahmsdaorf HJ, Park KK, Cato AC, Gebel S, Ponta H, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990;62:1189-204.
41. Lucibello FC, Slater EP, Jooss KU, Beato M, Muller R. Mutual transrepression of Fos and the glucocorticoid receptor: involvement of a functional domain in Fos which is absent in FosB. EMBO J 1990;9:2827-34.
42. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, et al. Transcriptional interference between c-Jun and glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990;62:1205-15.
43. Shemshedini L, Knauthe R, Sassone-Corsi P, Pornon A, Gronemeyer H. Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors. EMBO J 1991;10:3839-49.
44. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, et al. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997;272:17485-94.
45. Bubulya A, Wise SC, Shen XQ, Burmeister LA, Shemshedini L. c-Jun can mediate androgen receptor-induced transactivation. J Biol Chem 1996;271:24583-9.
46. Kallio PJ, Poukka H, Moilanen A, Janne OA, Palvimo JJ. Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element. Mol Endocrinol 1995;9:1017-28.
47. Schreck R, Albermann K, Baeuerle PA. Nuclear factor κB: an oxidative stress-responsive transcription factor of eurkaryotic cells (a review). Free Radic Res Commun 1992;17:221-37.